SecBot SecBot
8-K ·Filed Jun 25, 2026

LGND

LIGAND PHARMACEUTICALS INC
MIXED
Impact 6/10
Horizonweeks Processed4mo ago SEC0001193125-26-282990
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ◆ Mixed

Monitor the conversion premium and stock price relative to the conversion price ($334.27). If LGND trades above the conversion price, volatility and volume may increase due to convertible arbitrage activity. Also watch for updates on the XOMA acquisition closing and integration.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$303.59
T+0 close · Jun 25, 2026 · via day close
Latest settled
−4.45%
T+60 · $290.07
Vs SPY
−10.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 26 $303.59entry
  2. T+1 · 5mo ago +3.44%α +1.79% · $314.04
  3. T+5 · 4mo ago +5.26%α +3.09% · $319.55
  4. T+20 · 4mo ago −0.47%α −1.74% · $302.15
  5. T+60 · 8w ago −4.45%α −10.56% · $290.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ligand Pharmaceuticals issued $700M of 0.00% Convertible Senior Notes due 2031, with an initial conversion price of approximately $334.27 per share, and concurrently entered into a bond hedge (capped call) and warrant transactions to manage dilution. The proceeds are intended to help fund the pending acquisition of XOMA Royalty Corporation. The capital raise introduces dilution risk but is partially offset by the bond hedge, while the warrants add additional potential dilution if the stock exceeds the strike price.

Key Financial Metrics

Offering Size
$700.0M

Key Facts

  • Issued $700,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2031
  • Initial conversion rate of 2.9916 shares per $1,000 principal, equating to an initial conversion price of ~$334.27 per share
  • Notes are zero-coupon and mature on September 15, 2031
  • Bond hedge (capped call) and warrant transactions entered into with dealers to manage dilution and provide additional upside exposure
  • Proceeds likely used to fund the acquisition of XOMA Royalty Corporation (announced April 27, 2026)

Financial Impact

Up to 2.09 million shares of dilution upon full conversion of notes, plus further dilution from warrants if stock exceeds warrant strike; offset by bond hedge that reduces dilution at higher stock prices.

dilutioncapital structuredebt

Risk Factors

  • Dilution from note conversion and warrants could pressure EPS
  • Increased leverage from $700M debt obligation
  • Potential overhang from the convertible offering and related hedging activities

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-282990
Document: d167360dex101.htm0001193125-26-282990
Document: d167360dex102.htm0001193125-26-282990

US Market Status

Market Closed · Opens in 8h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 25, 2026